Celltrion, Inc. Overview
Pro stress-test →Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. The company offers biosimilars including Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for non-hodgkin's lymphoma, Herzuma for metastatic breast and gastric cancer, and multiple other therapeutic products. Celltrion provides one-stop solutions for the entire process of biopharmaceutical business from R&D to clinical trials, regulatory affairs, production and distribution.
Strategic Profile
Pro stress-test →Celltrion is transitioning from biosimilar excellence to next-generation innovative therapeutics with plans to expand manufacturing and R&D capabilities in the U.S. to support long-term growth and enhance supply resilience. Following a record year in 2025, Celltrion has entered a full-scale growth phase, targeting consolidated revenue of KRW 5.3 trillion in 2026.
Competitive Landscape
Pro stress-test →Key competitors include Samsung Biologics, ALTEOGEN, Voronoi, and SK bioscience within South Korea's biosimilar sector. Celltrion competes globally with international biosimilar manufacturers while establishing differentiation through manufacturing scale and innovative pipeline development focused on ADCs and multi-specific antibodies.
Industry Context
Celltrion, Inc. operates in Biopharmaceutical/Biotechnology - Biosimilars & Innovative Therapeutics.
Key facts
Founded: 2002 · Headquarters: Incheon, South Korea · Employees: 2680 · Revenue: $2.6B (2024) · Market cap: $37.8B